Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Patrick Angibaud"'
Autor:
Matthew V. Lorenzi, Sylvie Laquerre, Patrick Angibaud, Christopher Moy, Jayaprakash D. Karkera, Suso J. Platero, Jennifer Yang, Liang Xie, Na Cheng, David R. Newell, Neil T. Thompson, George Ward, Ron Gilissen, Christopher W. Murray, Martin Page, Gordon Saxty, Matthew Squires, David C. Rees, Eddy Freyne, Peter King, Kelly Van De Ven, Caroline Paulussen, Tinne Verhulst, Desiree De Lange, Jorge Vialard, Laurence Mevellec, Eleonora Jovcheva, Timothy P.S. Perera
A) Structure of JNJ-42541707, a structurally related compound to JNJ-42756493. B) 72h growth inhibition (IC50) of JNJ-42541707 against 236 cancer cell lines from multiple origins color coded based on FGFR1,2,4 mRNA overexpression and FGFR WT.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::014876daf0ea3141cec8e46d4cd3afe8
https://doi.org/10.1158/1535-7163.22503741
https://doi.org/10.1158/1535-7163.22503741
Autor:
Neil T. Thompson, David R. Newell, Christopher Murray, Julie Irving, John Lyons, Eddy Freyne, Edward J. Lewis, Jose Cosme, Andrew Pike, Brent L. Graham, Lindsay A. Devine, Susanne Bethell, Abarna Thiru, Ruth Feltell, Darcey Miller, Maria Carr, Sharna Rich, Michael A. Batey, Christopher Hamlett, Michael Reader, Martyn Frederickson, Alistair O'Brien, Emma Vickerstaffe, Rajdeep K. Benning, Andrew Madin, Charlotte Griffiths Jones, Douglas Ross, Lynsey Fazal, Tim Perera, Patrick Angibaud, Peter King, Anne Cleasby, Valerio Berdini, Gordan Saxty, George Ward, Matthew Squires
We describe here the identification and characterization of 2 novel inhibitors of the fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases. The compounds exhibit selective inhibition of FGFR over the closely related VEGFR2 rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::605eebdec9c9d2137ffcbba68a3b82cd
https://doi.org/10.1158/1535-7163.c.6535227
https://doi.org/10.1158/1535-7163.c.6535227
Autor:
Matthew V. Lorenzi, Sylvie Laquerre, Patrick Angibaud, Christopher Moy, Jayaprakash D. Karkera, Suso J. Platero, Jennifer Yang, Liang Xie, Na Cheng, David R. Newell, Neil T. Thompson, George Ward, Ron Gilissen, Christopher W. Murray, Martin Page, Gordon Saxty, Matthew Squires, David C. Rees, Eddy Freyne, Peter King, Kelly Van De Ven, Caroline Paulussen, Tinne Verhulst, Desiree De Lange, Jorge Vialard, Laurence Mevellec, Eleonora Jovcheva, Timothy P.S. Perera
In vitro kinase inhibition by DiscoverX KinomeScan assay. For details see (19)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::707b5abacc5ec387fe47990836d03d73
https://doi.org/10.1158/1535-7163.22503738
https://doi.org/10.1158/1535-7163.22503738
Autor:
Matthew V. Lorenzi, Sylvie Laquerre, Patrick Angibaud, Christopher Moy, Jayaprakash D. Karkera, Suso J. Platero, Jennifer Yang, Liang Xie, Na Cheng, David R. Newell, Neil T. Thompson, George Ward, Ron Gilissen, Christopher W. Murray, Martin Page, Gordon Saxty, Matthew Squires, David C. Rees, Eddy Freyne, Peter King, Kelly Van De Ven, Caroline Paulussen, Tinne Verhulst, Desiree De Lange, Jorge Vialard, Laurence Mevellec, Eleonora Jovcheva, Timothy P.S. Perera
Inhibitory activity of Brivanib and JNJ-42756943 in kinase (top) and BaF3 kinase dependent proliferation (bottom) assays and ratio of FGFRs/VEGFR2 activities.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60399ae060b7382e0f81605f3d51fc78
https://doi.org/10.1158/1535-7163.22503735
https://doi.org/10.1158/1535-7163.22503735
Autor:
Matthew V. Lorenzi, Sylvie Laquerre, Patrick Angibaud, Christopher Moy, Jayaprakash D. Karkera, Suso J. Platero, Jennifer Yang, Liang Xie, Na Cheng, David R. Newell, Neil T. Thompson, George Ward, Ron Gilissen, Christopher W. Murray, Martin Page, Gordon Saxty, Matthew Squires, David C. Rees, Eddy Freyne, Peter King, Kelly Van De Ven, Caroline Paulussen, Tinne Verhulst, Desiree De Lange, Jorge Vialard, Laurence Mevellec, Eleonora Jovcheva, Timothy P.S. Perera
JNJ-42756493 anti-proliferative activity against cancer cells lines from multiple origins.. Detailed data supporting Figure 2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59bca756040d98715cf3d679230a312d
https://doi.org/10.1158/1535-7163.22503732.v1
https://doi.org/10.1158/1535-7163.22503732.v1
Autor:
Neil T. Thompson, David R. Newell, Christopher Murray, Julie Irving, John Lyons, Eddy Freyne, Edward J. Lewis, Jose Cosme, Andrew Pike, Brent L. Graham, Lindsay A. Devine, Susanne Bethell, Abarna Thiru, Ruth Feltell, Darcey Miller, Maria Carr, Sharna Rich, Michael A. Batey, Christopher Hamlett, Michael Reader, Martyn Frederickson, Alistair O'Brien, Emma Vickerstaffe, Rajdeep K. Benning, Andrew Madin, Charlotte Griffiths Jones, Douglas Ross, Lynsey Fazal, Tim Perera, Patrick Angibaud, Peter King, Anne Cleasby, Valerio Berdini, Gordan Saxty, George Ward, Matthew Squires
PDF file - 475K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fe1a33d4a31585a984d85c6194526c9
https://doi.org/10.1158/1535-7163.22496319
https://doi.org/10.1158/1535-7163.22496319
Autor:
Patrick Angibaud, Kristof van Emelen, Martin Page, Michel Janicot, Marc Du Jardin, Luc Andries, Ilse Goris, Willem Talloen, Kees Bol, Eugene Cox, Veronique Vreys, Ian Hickson, Ron Gilissen, Laurence Decrane, Bruno Roux, Isabelle Pilatte, Lut Janssen, Ann Belin, Wim Floren, Ann Marin, Peter King, Janine Arts
Purpose: Histone deacetylase (HDAC) inhibitors have shown promising clinical activity in the treatment of hematologic malignancies, but their activity in solid tumor indications has been limited. Most HDAC inhibitors in clinical development only tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2434ea75f5b9b9c5f4fbdf2a8833ab91
https://doi.org/10.1158/1078-0432.c.6517927
https://doi.org/10.1158/1078-0432.c.6517927
Autor:
Patrick Angibaud, Kristof van Emelen, Martin Page, Michel Janicot, Marc Du Jardin, Luc Andries, Ilse Goris, Willem Talloen, Kees Bol, Eugene Cox, Veronique Vreys, Ian Hickson, Ron Gilissen, Laurence Decrane, Bruno Roux, Isabelle Pilatte, Lut Janssen, Ann Belin, Wim Floren, Ann Marin, Peter King, Janine Arts
Supplementary Data from JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a60eef472554e462da36d628bd346f
https://doi.org/10.1158/1078-0432.22440625.v1
https://doi.org/10.1158/1078-0432.22440625.v1
Autor:
Virginie Sophie Poncelet, Christophe Hoarau, Antoine Peresson, Thibaut Perse, Steven Frippiat, Christine Baudequin, Olivier Querolle, Cédric Schneider, Vincent Levacher, Patrick Angibaud, Lieven Meerpoel, Yvan Ramondenc, Laurent Bischoff
Publikováno v:
SYNLETT
SYNLETT, Georg Thieme Verlag, 2020, 31 (10), pp.1015-2021. ⟨10.1055/s-0040-1708003⟩
SYNLETT, Georg Thieme Verlag, 2020, 31 (10), pp.1015-1021. ⟨10.1055/s-0040-1708003⟩
SYNLETT, Georg Thieme Verlag, 2020, 31 (10), pp.1015-2021. ⟨10.1055/s-0040-1708003⟩
SYNLETT, Georg Thieme Verlag, 2020, 31 (10), pp.1015-1021. ⟨10.1055/s-0040-1708003⟩
International audience; The palladium-catalyzed arylation and alkenylation of N-substituted methyl imidazole-4-carboxylates are described through inter- and intramolecular pathways. Both direct C2–H and C5–H arylation and alkenylation proceed und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9434a083cc8e00032950a76fb30e594
https://hal-normandie-univ.archives-ouvertes.fr/hal-02548986
https://hal-normandie-univ.archives-ouvertes.fr/hal-02548986
Autor:
Peter King, Suso Platero, Matthew V. Lorenzi, Kelly Van De Ven, Caroline Paulussen, Liang Xie, Jennifer Yang, Jorge Vialard, Christopher Moy, Eleonora Jovcheva, Timothy Perera, David R. Newell, Jayaprakash Karkera, Sylvie Laquerre, Martin Page, Ron Gilissen, David C. Rees, Neil T. Thompson, George Ward, Desiree De Lange, Laurence Anne Mevellec, Patrick Angibaud, Matthew S Squires, Tinne Verhulst, Na Cheng, Eddy Jean Edgard Freyne, Christopher William Murray, Gordon Saxty
Publikováno v:
Molecular Cancer Therapeutics. 16:1010-1020
Fibroblast growth factor (FGF) signaling plays critical roles in key biological processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer. Genetic alterations in FGF receptor (FGFR) family members are a